Balance Sheet
Accounts PayablesAccumulated DepreciationAccumulated ExpensesAssetsCash & EquivalentsCommon EquityCurrent AssetsCurrent LeasesGoodwill & IntangiblesIntangiblesLiabilities and Shareholders EquityNon-Current AssetsOperating LeasesOther Accumulated ExpensesOther Non-Current AssetsOther Non-Current LiabilitiesPayablesPrepaid AssetsProperty, Plant & Equipment (Net)ReceivablesReceivables - AccuredRetained EarningsShareholder's EquityTotal Current LiabilitiesTotal LiabilitiesTotal Non-Current Liabilities
Cash Flow Statement
Daily Values
Growth Metrics
Income Statement
Others
Ratios

Celldex Therapeutics (CLDX) Assets (2016 - 2025)

Celldex Therapeutics has reported Assets over the past 16 years, most recently at $583.0 million for Q4 2025.

  • Quarterly results put Assets at $583.0 million for Q4 2025, down 26.42% from a year ago — trailing twelve months through Dec 2025 was $583.0 million (down 26.42% YoY), and the annual figure for FY2025 was $583.0 million, down 26.42%.
  • Assets for Q4 2025 was $583.0 million at Celldex Therapeutics, down from $648.4 million in the prior quarter.
  • Over the last five years, Assets for CLDX hit a ceiling of $868.8 million in Q1 2024 and a floor of $204.6 million in Q2 2021.
  • Median Assets over the past 5 years was $452.4 million (2021), compared with a mean of $512.0 million.
  • Biggest five-year swings in Assets: skyrocketed 193.72% in 2024 and later fell 26.42% in 2025.
  • Celldex Therapeutics' Assets stood at $444.7 million in 2021, then decreased by 20.67% to $352.7 million in 2022, then skyrocketed by 32.0% to $465.6 million in 2023, then skyrocketed by 70.17% to $792.3 million in 2024, then fell by 26.42% to $583.0 million in 2025.
  • The last three reported values for Assets were $583.0 million (Q4 2025), $648.4 million (Q3 2025), and $692.4 million (Q2 2025) per Business Quant data.